報價延遲最少15分鐘:2025/01/12 03:46 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.18 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.55/-2.41
|
|
企業價值
32.49M
|
| 資產負債 |
|
每股賬面淨值
1.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.28M
|
|
每股收益
2.12
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:46 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents anapproach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany. |